Trainline Plc (LON:TRN – Get Free Report)’s share price hit a new 52-week high on Thursday . The company traded as high as GBX 442.20 ($5.58) and last traded at GBX 434.80 ($5.49), with a volume of 795649 shares traded. The stock had previously closed at GBX 433.40 ($5.47).
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on the company. Berenberg Bank boosted their price objective on Trainline from GBX 475 ($6.00) to GBX 490 ($6.18) and gave the company a “buy” rating in a research note on Thursday, November 7th. Shore Capital reissued a “buy” rating on shares of Trainline in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Trainline from GBX 438 ($5.53) to GBX 500 ($6.31) and gave the stock an “overweight” rating in a research report on Thursday, December 5th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of GBX 456.25 ($5.76).
Read Our Latest Research Report on Trainline
Trainline Price Performance
Insider Activity
In related news, insider Marie Lalleman acquired 4,950 shares of the stock in a transaction dated Friday, November 8th. The stock was purchased at an average cost of GBX 400 ($5.05) per share, with a total value of £19,800 ($24,990.53). Corporate insiders own 4.08% of the company’s stock.
About Trainline
Trainline Plc engages in the operation of an independent rail and coach travel platform that sells rail and coach tickets the United Kingdom and internationally. It operates through three segments: UK Consumer, International Consumer, and Trainline Solutions. The UK Consumer segment provides travel apps and websites for individual travelers for journeys within the United Kingdom.
Further Reading
- Five stocks we like better than Trainline
- Top Biotech Stocks: Exploring Innovation Opportunities
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- NYSE Stocks Give Investors a Variety of Quality Options
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Pros And Cons Of Monthly Dividend Stocks
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Trainline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trainline and related companies with MarketBeat.com's FREE daily email newsletter.